VintafolideCAS# 742092-03-1 |
- Olprinone Hydrochloride
Catalog No.:BCC1821
CAS No.:119615-63-3
- Sildenafil
Catalog No.:BCC1947
CAS No.:139755-83-2
- Vardenafil HCl Trihydrate
Catalog No.:BCC2277
CAS No.:224785-90-4
- Aminophylline
Catalog No.:BCC2300
CAS No.:317-34-0
- Dyphylline
Catalog No.:BCC2297
CAS No.:479-18-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 742092-03-1 | SDF | Download SDF |
PubChem ID | 25014653 | Appearance | Powder |
Formula | C86H109N21O26S2 | M.Wt | 1917.04 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
Chemical Name | (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(1R)-1-carboxy-2-[2-[[[(1R,9R,10S,11R,12R,19R)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carbonyl]amino]carbamoyloxy]ethyldisulfanyl]ethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid | ||
SMILES | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)NNC(=O)OCCSSCC(C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(=O)O)NC(=O)CCC(C(=O)O)NC(=O)C1=CC=C(C=C1)NCC1=CN=C2C(=N1)C(=O)NC(=N2)N)O)O)CC)OC)C(=O)OC)O | ||
Standard InChIKey | KUZYSQSABONDME-QRLOMCMNSA-N | ||
Standard InChI | InChI=1S/C86H109N21O26S2/c1-6-82(129)35-42-36-85(78(127)132-5,64-47(21-26-106(39-42)41-82)46-12-8-9-13-50(46)95-64)49-30-48-57(34-58(49)131-4)105(3)75-84(48)23-27-107-25-11-22-83(7-2,74(84)107)76(125)86(75,130)77(126)103-104-81(128)133-28-29-134-135-40-56(73(123)124)100-70(119)55(33-62(113)114)99-69(118)54(32-61(111)112)98-67(116)51(14-10-24-90-79(87)88)96-68(117)53(31-60(109)110)94-59(108)20-19-52(72(121)122)97-66(115)43-15-17-44(18-16-43)91-37-45-38-92-65-63(93-45)71(120)102-80(89)101-65/h8-9,11-13,15-18,22,30,34,38,42,51-56,74-76,91,95,125,129-130H,6-7,10,14,19-21,23-29,31-33,35-37,39-41H2,1-5H3,(H,94,108)(H,96,117)(H,97,115)(H,98,116)(H,99,118)(H,100,119)(H,103,126)(H,104,128)(H,109,110)(H,111,112)(H,113,114)(H,121,122)(H,123,124)(H4,87,88,90)(H3,89,92,101,102,120)/t42-,51-,52-,53-,54-,55-,56-,74-,75+,76+,82-,83+,84+,85-,86-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Vintafolide Dilution Calculator
Vintafolide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 0.5216 mL | 2.6082 mL | 5.2164 mL | 10.4328 mL | 13.0409 mL |
5 mM | 0.1043 mL | 0.5216 mL | 1.0433 mL | 2.0866 mL | 2.6082 mL |
10 mM | 0.0522 mL | 0.2608 mL | 0.5216 mL | 1.0433 mL | 1.3041 mL |
50 mM | 0.0104 mL | 0.0522 mL | 0.1043 mL | 0.2087 mL | 0.2608 mL |
100 mM | 0.0052 mL | 0.0261 mL | 0.0522 mL | 0.1043 mL | 0.1304 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3-Bromo-7-nitroindazole
Catalog No.:BCC6770
CAS No.:74209-34-0
- Uplandicine
Catalog No.:BCN2055
CAS No.:74202-10-1
- Doxazosin
Catalog No.:BCC4218
CAS No.:74191-85-8
- Cyclokievitone
Catalog No.:BCC8159
CAS No.:74175-82-9
- Haginin A
Catalog No.:BCN6861
CAS No.:74174-29-1
- R547
Catalog No.:BCC3927
CAS No.:741713-40-6
- 2,3-Dehydrokievitone
Catalog No.:BCN4294
CAS No.:74161-25-4
- Pimobendan
Catalog No.:BCC2294
CAS No.:74150-27-9
- Bisdethiobis(methylthio)gliotoxin
Catalog No.:BCN7351
CAS No.:74149-38-5
- DSC
Catalog No.:BCC2800
CAS No.:74124-79-1
- Norjuziphine
Catalog No.:BCN3367
CAS No.:74119-87-2
- SKF 83822 hydrobromide
Catalog No.:BCC7252
CAS No.:74115-10-9
- Carbenoxolone disodium
Catalog No.:BCC3745
CAS No.:7421-40-1
- OSU-03012 (AR-12)
Catalog No.:BCC1255
CAS No.:742112-33-0
- Doronenine
Catalog No.:BCN2066
CAS No.:74217-57-5
- Baogongteng A
Catalog No.:BCN1874
CAS No.:74239-84-2
- p-Chlorophenylalanine
Catalog No.:BCC5689
CAS No.:7424-00-2
- 7-Acetylintermedine
Catalog No.:BCN1998
CAS No.:74243-01-9
- 12-Oxograndiflorenic acid
Catalog No.:BCN7624
CAS No.:74284-42-7
- Triptophenolide
Catalog No.:BCN2546
CAS No.:74285-86-2
- Sinapine thiocyanate
Catalog No.:BCN2765
CAS No.:7431-77-8
- Quercetin-3-gentiobioside
Catalog No.:BCN3878
CAS No.:7431-83-6
- Somatostatin 1-28
Catalog No.:BCC5715
CAS No.:74315-46-1
- Z-Trp-OH
Catalog No.:BCC2750
CAS No.:7432-21-5
Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.[Pubmed:27654255]
Int J Gynecol Cancer. 2016 Nov;26(9):1580-1585.
OBJECTIVE: This exploratory analysis evaluated the incidence of adverse events (AEs) by folate receptor (FR) status in the randomized, multicenter, open-label PRECEDENT study in women with platinum-resistant ovarian cancer receiving pegylated liposomal doxorubicin (PLD) +/- the small-molecule drug conjugate Vintafolide. METHODS: Women 18 years or older with platinum-resistant ovarian cancer were randomized 2:1 to Vintafolide (2.5 mg intravenously, 3 times per week, weeks 1 and 3, every 28 days) + PLD (50 mg/m intravenously, day 1, every 28 days) or PLD alone (same dose/schedule). The expression of functionally active FR was evaluated by single-photon emission computed tomography with etarfolatide. Patients were categorized according to FR positivity: patients with all target lesions positive for FR expression (FR 100%), patients with 1 or more but not all target lesions positive for FR expression (FR 10%-90%), and patients with all lesions negative for FR expression (FR 0%). RESULTS: Data on FR status were available for 94 patients: 38 were FR 100%, 36 were FR 10% to 90%, and 20 were FR 0%. Across all FR subgroups, the duration of treatment was longer, and the number of cycles was higher in combination-therapy arms than PLD-alone arms. Although the frequency of AEs was relatively consistent across subgroups, the FR 100% subgroup had a higher incidence of patients with at least 1 AE for combination therapy versus PLD alone. No surprising safety signals were shown according to FR status. The incidence of grade 3 or 4 treatment-emergent drug-related AEs was generally low across all FR subgroups and treatment arms. CONCLUSIONS: This exploratory analysis suggests that FR status does not influence the AE profile of Vintafolide + PLD combination therapy or PLD alone in patients with platinum-resistant ovarian cancer. Future a priori analyses in larger populations are needed to confirm these findings.
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.[Pubmed:27256377]
Mol Cancer Ther. 2016 Aug;15(8):1998-2008.
Targeting surface receptors overexpressed on cancer cells is one way to specifically treat cancer versus normal cells. Vintafolide (EC145), which consists of folate linked to a cytotoxic small molecule, desacetylvinblastine hydrazide (DAVLBH), takes advantage of the overexpression of folate receptor (FR) on cancer cells. Once bound to FR, Vintafolide enters the cell by endocytosis, and the reducing environment of the endosome cleaves the linker, releasing DAVLBH to destabilize microtubules. Vintafolide has shown efficacy and improved tolerability compared with DAVLBH in FR-positive preclinical models. As the first FR-targeting drug to reach the clinic, Vintafolide has achieved favorable responses in phase II clinical trials in FR-positive ovarian and lung cancer. However, some FR-positive patients in these clinical trials do not respond to Vintafolide. We sought to identify potential biomarkers of resistance to aid in the future development of this and other FR-targeting drugs. Here, we confirm that high P-glycoprotein (P-gp) expression was the strongest predictor of resistance to DAVLBH in a panel of 359 cancer cell lines. Furthermore, targeted delivery of DAVLBH via the FR, as in Vintafolide, fails to overcome P-gp-mediated efflux of DAVLBH in both in vitro and in vivo preclinical models. Therefore, we suggest that patients whose tumors express high levels of P-gp be excluded from future clinical trials for Vintafolide as well as other FR-targeted therapeutics bearing a P-gp substrate. Mol Cancer Ther; 15(8); 1998-2008. (c)2016 AACR.
Vintafolide: a novel targeted agent for epithelial ovarian cancer.[Pubmed:24754586]
Future Oncol. 2014 Mar;10(4):541-8.
Vintafolide (EC145) is a novel folate-conjugated vinca alkaloid (desacetylvinblastine hydrazide; DAVBLH) that binds with high affinity to the folate receptor (FR), expressed in a majority of epithelial ovarian cancers. In preclinical studies, Vintafolide had significant antiproliferative activity and tolerability. Phase I studies demonstrated an acceptable safety profile, with constipation being the dose-limiting toxicity. A Phase II study of Vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in patients with platinum-resistant ovarian cancer showed a statistically significant improvement in progression-free survival with combination therapy. (99m)Tc-etarfolatide, a diagnostic radiopharmaceutical, determines FR status, which allows determination of those patients most likely to benefit from treatment with Vintafolide. A Phase III study evaluating Vintafolide plus PLD versus PLD alone in patients with platinum-resistant ovarian cancer is currently underway.
Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.[Pubmed:26136852]
Ther Adv Med Oncol. 2015 Jul;7(4):206-18.
Despite advances in the development of molecularly targeted therapies, limited improvements in overall survival have been noted among many cancer patients with solid tumors, primarily due to development of drug resistance. Accordingly, there is an unmet need for new targeted therapies and treatment approaches for cancer, especially for overcoming resistance. Expression of the folate receptor is upregulated in many tumor types and thus represents an ideal target for cancer treatment. Several folate receptor targeted therapies are in development, including the small molecule drug conjugate Vintafolide, the monoclonal antibody farletuzumab, and the antibody-drug conjugate IMGN853. The role of the folate receptor as a target in cancer progression and resistance as well as emerging preclinical and clinical data from studies on those folate receptor targeted agents that are in development with a focus on Vintafolide are reviewed. The folate receptor has several unique properties, such as high expression in several tumor types, that make it a rational target for cancer treatment, and allow for selective delivery of folate receptor targeted agents. Early-stage clinical data in lung and ovarian cancer suggest that Vintafolide has the potential for combination with other standard approved agents.